Peptide
FOXO4-DRI
SaveA D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, triggering selective apoptosis of those cells (senolytic activity).
Quick verdict
Striking results in aged mice (restored fur, fitness, renal function). No human trials. Extremely expensive to synthesize.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
One landmark 2017 paper in Cell demonstrated senolytic effects in naturally aged mice. No follow-up human trials. Synthesis cost is prohibitive for most.
Benefits
- Selective senescent cell clearance in mice
- Improved physical fitness and organ function in aged mice
Dosage notes
Mouse study used high doses relative to body weight. No human dosing established.
Side effects
- Unknown in humans
- Theoretical off-target apoptosis
- Injection-site reactions
Who should be cautious
No human safety data. Senolytic mechanisms could theoretically affect non-senescent cells. Gray-market products are of questionable authenticity.
What this page cannot tell you
Single mouse study, not replicated in humans. Cost and synthesis complexity are significant barriers.
Leaderboard scores
- Longevity30
Write a review
Sign in to write a review.